Tanistry

Tanistry is a pre-clinical stage biotechnology company focused on developing next-generation precision medicines for oncology. The company specializes in the discovery of selective small molecule inhibitors targeting cyclin-dependent kinases (CDKs), specifically focusing on CDK2 and CDK4/6 pathways to overcome resistance in solid tumors. By leveraging advanced structural biology and medicinal chemistry, Tanistry aims to create therapies with improved therapeutic indices and better safety profiles compared to existing cell cycle inhibitors. Their lead programs are currently directed toward treating hormone receptor-positive breast cancer and other CDK-dependent malignancies.